Select Page
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions

Validated Phenotypic Approach to Neuropsychiatric Drug Discovery

Leahy E Drug Development & Delivery March 2019 Vol 19 No 2: 46-49. At the recent American College of Neuropsychopharmacology (ACNP) meeting, Sunovion Pharmaceuticals and PsychoGenics Inc. announced positive Phase 2 results for SEP-363856, a novel, first-in-class...